Abstract PS2-07: Intrinsic Subtype at Progression to CDK4/6 Inhibitors Plus Endocrine Therapy in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer (MBC)
Isabel García-Fructuoso(Breast Cancer Research Foundation), Francesco Schettini(Breast Cancer Research Foundation), Valeria Sirenko(Breast Cancer Research Foundation), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Angela Aguirre, Raquel Gómez Bravo(Breast Cancer Research Foundation), Oleguer Castillo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Sabrina Nucera(University of Catania), Blanca González‐Farré(Hospital Clínic de Barcelona), Tomás Pascual(Breast Cancer Research Foundation), María Vidal(Inserm), Patricia Galván(Vall d'Hebron Institute of Oncology), Paula Blasco(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Olga Martínez‐Sáez(Breast Cancer Research Foundation), Esther Sanfeliu(Hospital Clínic de Barcelona), Natàlia Lorman-Carbó, Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Aleix Prat(Hospital Clínic de Barcelona), Elia Seguí, Benjamín Walbaum, Bárbara Adamo(Hospital Clínic de Barcelona)
Cited by 3
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k
Non-coding recurrent mutations in chronic lymphocytic leukaemia
|Nature|2015|851